Using phage therapy to treat bladder infections in spinal cord injury patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 1b study evaluates the safety and tolerability of personalized bacteriophage therapy in adults with spinal cord injuries who have asymptomatic bacteriuria caused by E. coli. Participants will be randomly assigned to receive either the phage therapy or a placebo, administered directly into the bladder via catheter for seven days. The study aims to assess the pharmacokinetics and pharmacodynamics of the treatment, with follow-up assessments conducted over a 35-day period post-treatment. Approximately 30 participants will be enrolled, focusing on those with neurogenic bladders requiring catheterization.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Provision of signed and dated informed consent form.
2. Stated willingness to comply with all study procedures and availability for the duration of the study.
3. Adult (\> age 18) with a diagnosis of Spinal Cord Injury/Disease (SCI/D) and neurogenic bladder. Eligible participants may include inpatients in the SCI care unit or outpatients receiving care at participating sites, regardless of the underlying cause of SCI (e.g., trauma, tumors or demyelinating).
4. ASB with E. coli present in a quantity of ≥ 104 CFU/mL.
5. Require an indwelling (transurethral or suprapubic) or intermittent catheterization for bladder drainage.
6. Women of childbearing potential and men with female partners of childbearing potential must use two forms of effective contraception during the study and for two weeks afterwards.
7. Participant will be hospitalized during the 7 days of treatment or will be willing to attend clinic visits either (a) daily for the 7 days of treatment, or (b) on Day 1 and Day 7 of dosing. On Day 1, the participant will receive in-person training on instillation of the IP into the bladder.

Exclusion Criteria:

1. Unable to provide informed consent for themselves.
2. Received a new antibiotic expected to kill the Gram-negative organisms in the urine between initial enrollment urine culture and the time of randomization.
3. History of neutropenia, defined by ANC \< 1000 per µL within 6 months prior to screening.
4. History of organ transplantation.
5. Presence of a surgically modified bladder, except for a repaired ruptured bladder.
6. HIV with a CD4 count \< 200 cells per µL.
7. Unstable vital signs (e.g., fever, hypotension)
8. Symptoms of active urinary tract infection defined as fever, autonomic dysreflexia, generalized increase in spasticity, bladder spasms, new sweating, increase or change in lower abdominal pain, increase in burning or pain when passing urine, increase in burning or pain during catheterization, blood in the urine, or an increased sensation of urinary urgency (MedStar Health, Urinary Symptom Questionnaires for Neurogenic Bladder \[USQNB\]). The presence of any one of these symptoms, unless explained by a non-urinary or non-infectious condition, will be an exclusion criterion.
9. Known urinary obstruction.
10. Medical devices in the urinary tract (other than urinary catheters)
11. Unless deemed acceptable by the sponsor-investigator, prescription drugs, OTC medications and supplements that acidify the urine are excluded.
12. Stage 4 or greater chronic kidney disease
13. Pregnant or breastfeeding female
14. Three or more episodes of autonomic dysreflexia in prior 30 days; defined as those patients who have a SCI and who have had a documented sudden increase in systolic blood pressure of greater than 40 mmHg due to an irritation or stimulation (including bladder or bowel irritation) below the level of the SCI. Autonomic dysreflexia can include findings of hypertensive crisis or emergency, clinically significant bradycardia/tachycardia, severe headache or other severe reaction requiring an acute intervention. The sponsor-investigator will evaluate if a history of severe autonomic dysreflexia is suspected but not clearly identified.
15. In the opinion of the sponsor-investigator, medical or psychiatric illness that would interfere with participation such as active, severe, progressive, or uncontrolled hepatic, hematologic, gastrointestinal, endocrine, pulmonary, cardiac, or neurologic disease.

Where it's running

• Washington University in St Louis
  St Louis, Missouri, United States Recruiting
• Michael E. DeBakey VA Medical Center
  Houston, Texas, United States Recruiting

Study contacts

• Principal investigator: Barbara W Trautner, MD, PhD — Washington University School of Medicine
• Study coordinator: Barbara W Trautner, MD, PhD
• Email: trautner@wustl.edu
• Phone: 314 747 5258

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Transcutaneous spinal cord stimulation with 4-aminopyridine and intensive rehab for chronic spinal cord injury

  This pilot study tests whether combining noninvasive spinal stimulation, dalfampridine, and rigorous rehab is safe and feasible for adults with chronic spinal cord injury and whether it can help improve movement and walking.

  Recruiting TryAbility LLC · Downers Grove, Illinois · NCT07922122

• NG004 for incomplete cervical spinal cord injury

  This trial tests NG004 versus placebo to see if it is safe and helps motor function and daily life in adults with acute incomplete cervical spinal cord injury.

  Recruiting at 7 sites Phase 1 NovaGo Therapeutics AG · Bayreuth and 9 other locations · NCT07840196

• Robot-assisted training for arm and leg movement after stroke or injury

  This study tests whether adding ZEPU-AI robotic training to usual therapy is safe and helps adults with arm or leg movement problems from stroke, spinal cord injury, brain injury, or orthopedic conditions.

  Recruiting Bangladesh Medical University · Dhaka · NCT07749625

• ZEPU-AI3 Lower Limb Feedback Training and Evaluation Robot in Rehab

  This pilot trial tests whether adding the ZEPU-AI3 robotic leg training with real-time feedback to standard rehab helps adults with lower limb motor problems from stroke, spinal cord injury, or similar conditions.

  Recruiting Bangladesh Medical University · Dhaka, Dhaka Division · NCT07705906

• Combined magnetic stimulation and ultrasound for detrusor overactivity in spinal cord injury

  This study tests whether using high-frequency sacral nerve stimulation together with bladder-directed ultrasound can reduce involuntary bladder contractions and improve bladder function in people with spinal cord injury.

  Recruiting Shengjing Hospital · Shenyang · NCT07704268

• Hybrid HIIT-FES cycling program for people with spinal cord injury

  This study tests a hybrid exercise program that combines functional electrical stimulation cycling with voluntary arm work to improve health in adults with spinal cord injury.

  Recruiting William Carey University · Hattiesburg, Mississippi · NCT07648173

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.